Alder Biopharmaceuticals Inc (ALDR.OQ)
20 Jul 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2018||President, Chief Executive Officer|
|40||2018||Chief Operating Officer|
|56||2016||Executive Vice President, Principal Accounting Officer|
|55||2018||Chief Commercial Officer and Executive Vice President of Corporate Strategy|
|51||2016||Senior Vice President, General Counsel|
- BRIEF-Alder Biopharmaceuticals Reports Q1 Loss Per Share Of $1.73
- BRIEF-Alder Biopharmaceuticals Appoints Jeremy Green To Its Board Of Directors
- BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine
- BRIEF-Alder Biopharmaceuticals Presents New 12-Month Data Of Eptinezumab In Promise 1 Phase 3 Trial
- BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab